NSJ Bioreagents

B-Cell Marker Antibodies Overview

B-Cell Marker Antibodies target proteins that define the identity, differentiation, and function of B lymphocytes. B cells are central to adaptive immunity, producing antibodies and serving as antigen-presenting cells. They progress through distinct developmental stages in the bone marrow and peripheral lymphoid tissues, with each stage characterized by the expression of specific surface markers such as CD19, CD20, CD21, CD22, and CD79a.

These markers are not only important for basic immunology but also serve as diagnostic and therapeutic targets in diseases such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune disorders. The B-Cell Marker Antibodies portfolio provides validated reagents for identifying B cells, characterizing subsets, and studying their roles in health and disease.

Why Choose B-Cell Marker Antibodies from NSJ Bioreagents?

NSJ Bioreagents provides B-Cell Marker Antibodies validated for immunohistochemistry, western blotting, flow cytometry, immunofluorescence, and ELISA. Each B-Cell Marker Antibody undergoes strict validation to ensure specificity, reproducibility, and performance across a range of immunological applications.

By selecting B-Cell Marker Antibodies from NSJ Bioreagents, researchers gain reagents optimized for clarity and consistency. Our antibodies deliver strong staining in lymphoid tissue, reproducible detection in protein lysates, and dependable performance across experimental workflows. Detailed datasheets, validated controls, and optimized protocols further ensure reproducibility in both discovery and clinical research.

Applications of B-Cell Marker Antibodies

The B-Cell Marker Antibodies portfolio supports diverse applications in immunology, oncology, and translational medicine.

1) Immunology and Immune Profiling

B-Cell Marker Antibodies identify subsets including naïve, memory, and plasma cells.
The B-Cell Marker Antibodies support studies of antigen presentation and antibody production.
Antibodies clarify B-cell involvement in immune tolerance and autoimmunity.

2) Oncology and Hematological Malignancies

B-Cell Marker Antibodies detect CD19, CD20, and related markers in leukemias and lymphomas.
The B-Cell Marker Antibodies support diagnosis, classification, and prognosis in B-cell cancers.
Antibodies validate biomarkers for therapeutic response and resistance.

3) Autoimmune and Chronic Inflammatory Diseases

B-Cell Marker Antibodies highlight altered B-cell populations in lupus, rheumatoid arthritis, and multiple sclerosis.
The B-Cell Marker Antibodies support profiling of autoreactive clones.
Antibodies contribute to biomarker panels for autoimmunity.

4) Therapeutic Targeting

B-Cell Marker Antibodies track targets of monoclonal therapies such as rituximab (anti-CD20).
The B-Cell Marker Antibodies support pharmacodynamic monitoring.
Antibodies validate novel therapeutic strategies against B-cell subsets.

5) Transplantation and Tolerance

B-Cell Marker Antibodies identify roles for B cells in graft rejection and tolerance.
The B-Cell Marker Antibodies support immune monitoring in transplantation studies.
Antibodies clarify B-cell–driven mechanisms in graft outcomes.

6) Translational and Clinical Research

B-Cell Marker Antibodies are applied in biomarker-driven oncology and immunology trials.
The B-Cell Marker Antibody supports patient stratification and therapy selection.
Antibodies ensure reproducibility across translational workflows.

Why Are B-Cell Marker Antibodies Important?

B cells are critical players in adaptive immunity, serving as both antibody producers and regulators of immune responses. The B-Cell Marker Antibodies collection equips researchers to reliably study B-cell biology in basic, translational, and clinical contexts.

In immunology, B-Cell Marker Antibodies clarify the stages of B-cell development and their functional roles. In oncology, the B-Cell Marker Antibody provides diagnostic and prognostic information in lymphoid malignancies. In autoimmunity, B-Cell Marker Antibodies highlight dysregulated subsets that drive pathology.

Clinically, B-cell markers are targets of established and emerging therapies, making accurate detection essential for diagnostics, therapy monitoring, and precision medicine.

Conclusion

B cells are fundamental to adaptive immunity and central to numerous diseases. The B-Cell Marker Antibodies collection provides validated reagents for immunology, oncology, and translational research. By ensuring specificity, reproducibility, and assay versatility, these antibodies remain indispensable for advancing immune science and improving clinical outcomes.